Risk factors for CHC-related death identified
As reported in the World Journal of Gastroenterology, the following risk factors for chronic hepatitis C (CHC)-related deaths have been identified (n=8250 CHC patients; n=144 CHC-related deaths): α-IFN therapy (AOR=0.53); liver cirrhosis (AOR=2.89); hepatocellular carcinoma versus CHC (AOR=8.82); hypertension (AOR=1.76); alcohol consumption (AOR=1.73); and HBsAg positivity (AOR=22.28).
SIRT3 expression improves prognosis in gastric cancer
As reported in the World Journal of Surgery, SIRT3 expression improves the prognosis in patients with gastric cancer (n=221). Specifically, the 5-year OS was 51.2% and 39.1% in patients who do and do not express SIRT3, respectively. The 5-year DFS was 49.6% and 38.0% in patients who do and do not express SIRT3, respectively. Patients who do not express SIRT3 are characterized by increased poor cellular differentiation, increased diffuse-type Lauren’s histology, and increases scirrhous-type stromal reactions, suggesting the SIRT3 functions as a tumor suppressor.
SCCA-IgM predicts survival in HCC patients
As reported in the Journal of Gastroenterology & Hepatology, SCCA-IgM levels are elevated in patients with hepatocellular carcinoma (HCC) compared to patients with cirrhosis and healthy controls. Not only does the SCCA-IgM level predict overall and progression-free survival in HCC patients, but the sensitivity of SCCA-IgM in patients with HCC was 2-fold greater than AFP. A decline in SCCA-IgM levels was shown to be associated with response to treatment.